People Places Practices

medicines to help safeguard the lives of children
and adolescents living with HIV.
New Horizons Advancing Pediatric HIV
Care Collaborative
The New Horizons Advancing Pediatric HIV
Care Collaborative has quickly become a
fundamental component of our Company’s
ongoing commitment to improving the care of
children around the world and in our fight against
HIV. Since its launch in 2014, this first-of-itskind
program has expanded beyond donations
of medicines to emphasize health systems
strengthening and a holistic approach to care
for children and adolescents living with HIV,
including emotional and psychosocial support.
From training and tools to build health worker
capacity to data collection and publication to
share learnings, we are working to address
individual patient needs and foster holistic public
health approaches to care.
In 2015, the first New Horizons patients in
Kenya, Swaziland and Zambia received donated
HIV medicines from Janssen. Additionally,
independent experts including representatives
from partner organizations selected Lesotho—
the country with the second highest prevalence
of HIV globally—from applicants to the second
Expression of Interest to participate in New
Horizons. Also in 2015, efforts focused on building
health care worker capacity with “Resistance
Made Easy” workshops in Zambia, Kenya, South
Africa and Swaziland. These were in addition
to the second annual New Horizons Technical
Support Workshop in Johannesburg, highlighting
challenges and differences between countries
while generating enthusiasm for collaboration
and information sharing between countries.
In 2016, New Horizons will increase its focus
on adolescents living with HIV that need or
are receiving third-line treatment; enhanced
psychosocial support for adolescent HIV patients
especially when facing the unique challenges
when transitioning from pediatric to adult HIV
health care systems.
TUBERCULOSIS PATIENT NEEDS Efforts by Johnson & Johnson to address TB are part of an overall
Global Public Health commitment to measurably improve the lives of individuals, families and communities.
This includes working to help eliminate MDR-TB (multidrug-resistant) and XDR-TB (extensively drug
resistant), as well as simplifying treatment regimens for patients worldwide.
Global TB Access Framework
Janssen has a long legacy of working to improve
access to and appropriate use of medicines for
diseases of great unmet need, including HIV/AIDS,
TB and other diseases impacting the developing
world and emerging markets. In 2015 we
continued to leverage the power of partnerships to
increase the potential impact of our efforts, with a
particular emphasis on designing and deploying a
global TB access framework.
USAID—Bedaquiline Donation Program
Janssen is contributing an estimated $30 million
worth of its MDR-TB medicine, totaling 30,000
courses, for use in more than 100 low- and
middle-income Global Fund-eligible countries for
the treatment of MDR-TB. Janssen and the U.S.
Agency for International Development (USAID)
are working with national TB programs and
partners to provide sustainable access and ensure
appropriate use of SIRTURO ® (bedaquiline).
As part of these efforts, Janssen has entered
into a new Memorandum of Understanding
(MOU) with USAID that will widen the scope
of their engagement in the fight against
MDR-TB. With this new MOU, Janssen has
committed to expanding patient access to novel
2015 Citizenship & Sustainability Report 22